FDA Orange Book adds Zevra Therapeutics U.S. patent, extending rare disease treatment protection

FDA Orange Book adds Zevra Therapeutics U.S. patent, extending rare disease treatment protection
Zevra extends patent protection

Zevra Therapeutics announced the FDA Orange Book listing of a U.S. patent that extends the company's exclusivity protection through November 2041.

This move is aimed at advancing innovation for the rare disease community and further solidifies Zevra Therapeutics' intellectual property portfolio. The company emphasized that this milestone demonstrates its ongoing commitment to developing treatments for rare diseases, ensuring long-term protection and market position for its proprietary therapies.

Zevra Therapeutics recently presented findings from its NPC002 trial and a genotype analysis for Niemann-Pick disease Type C at SIMD2026 on May 18. The company also shared business updates during a fireside chat led by CEO Neil McFarlane at the H.C. Wainwright BioConnect Investor Conference on May 19. These activities reflect the company's continued engagement with both scientific and investor communities.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.